The Society for Clinical Research Sites (SCRS) is proud to announce the launch of its newest initiative, the Site Advocacy Group (SAG). SCRS is honored to have TransCelerate BioPharma Inc. (“TransCelerate”) as its SAG partner.
The SAG is a landmark industry initiative that enables clinical investigators and site professionals to interact directly with senior industry leaders in the exchange of perspectives and experiences on innovative ideas, processes, tools and technologies. The knowledge gained will help to promote site sustainability, enhance clinical research effectiveness and more closely align the work of the sites and industry across the research ecosystem.
“By bringing together the global site community, SCRS has actively advocated for the sustainability of all sites. The formation of the SAG is the most recent example,” stated Christine Pierre, President of the Society for Clinical Research Sites. “It marks a true coalescence of major industry stakeholders working together towards mutually beneficial and respectful outcomes with the sites. This commitment by TransCelerate, representing 19 major sponsors, demonstrates a true commitment to the site community through SCRS’ SAG.”